BOPA Immunotherapy Specialist Advisory Group (SAG) – Abstract Accepted to ESMO IO 2024

A message from the BOPA Immunotherapy SAG:

It brings us great pleasure to inform you that the Research & Analysis pillar of the BOPA Immunotherapy SAG has successfully submitted abstract to ESMO Immuno-Oncology Congress which has been accepted for poster presentation at their meeting 11-13 December 2024 in Geneva, Switzerland.

Title: Access to vedolizumab for the management of immune-related colitis (IRC) – A United Kingdom study

Authors: Coe, Faye; Desai, Meera; Kantilal, Kavita; Parkes, Joanne; Paterson, Kate; Tew, Alice

We would like to say thank you to the BOPA membership for engaging with the survey at the beginning of summer – we had a fantastic response!

Alice and I would also like to acknowledge and celebrate the hard work and voluntary hours put in by Faye, Kavita, Joanne, and Kate to be able to achieve this. We are excited to represent BOPA and the cancer pharmacy community at ESMO IO.

Kind Regards

Meera and Alice

For more information on the BOPA IO SAG – see their page here: BOPA Immunotherapy Specialist Advisory Group – BOPA